Pre-made Ponsegromab benchmark antibody ( Whole mAb, anti-GDF15 therapeutic antibody, Anti-GDF-15/MIC-1/MIC1/NAG-1/PDF/PLAB/PTGFB Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ponsegromab biosimilar, Whole mAb, Anti-GDF15 Antibody: Anti-GDF-15/MIC-1/MIC1/NAG-1/PDF/PLAB/PTGFB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ponsegromab (formerly PF 06946860) is a subcutaneously administered, growth factor inhibitor, being developed by Pfizer, for the treatment of cachexia.
| Products Name (INN Index) | Pre-Made Ponsegromab biosimilar, Whole mAb, Anti-GDF15 Antibody: Anti-GDF-15/MIC-1/MIC1/NAG-1/PDF/PLAB/PTGFB therapeutic antibody |
|---|---|
| INN Name | Ponsegromab |
| Target | GDF15 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Pfizer |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Cachexia |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | GDF15 |
| Package |
